Need Help?

Targeted panel data for newly diagnosed myeloma patients.

Genomic abnormalities in MM are common and can affect a patients outcome. Here we have performed targeted sequencing on xx patient tumor samples and matched control DNA. The targeted panel consists of ~160 genes and copy number regions, as well as key regions of chromosomal translocation including IGH, IGK, IGL and MYC. Using mutation, copy number, and translocation information we have been able to identify abnormalities that affect prognosis including bi-allelic inactivation of TP53 and rearrangements involving MYC.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004117 Illumina HiSeq 2500 200
EGAD00010001577 Affymetrix GeneChip Scanner 3000 7g 98
Publications Citations
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma.
Haematologica 102: 2017 e364-e367
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma.
Haematologica 105: 2020 1055-1066
TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use.
BMC Bioinformatics 21: 2020 144